Scarica l'app Stockscreener
0.00
100.00%
-90.00
Dopo l'orario di chiusura:
88.97
88.97
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRUS Giù?
Forum
Previsione
Precedente Chiudi:
$90.00
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$6.83B
Reddito:
$35.93M
Utile/perdita netta:
$-244.56M
Rapporto P/E:
0.00
EPS:
-3.95
Flusso di cassa netto:
$-157.31M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$97.14
Merus N V Stock (MRUS) Company Profile
Nome
Merus N V
Settore
Industria
Telefono
31 030 253 8800
Indirizzo
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
0.00 | 6.83B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.69 | 117.06B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.86 | 80.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
717.80 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.66 | 42.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
301.12 | 32.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-08-25 | Iniziato | Alliance Global Partners | Buy |
| 2025-02-13 | Iniziato | Piper Sandler | Overweight |
| 2025-02-07 | Iniziato | Wells Fargo | Overweight |
| 2024-11-21 | Iniziato | Goldman | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-03-28 | Iniziato | Truist | Buy |
| 2024-03-04 | Reiterato | Needham | Buy |
| 2023-11-02 | Iniziato | Canaccord Genuity | Buy |
| 2023-08-21 | Iniziato | TD Cowen | Outperform |
| 2022-08-02 | Iniziato | Stifel | Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Needham | Buy |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-06-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-08 | Iniziato | William Blair | Outperform |
| 2021-03-16 | Iniziato | SVB Leerink | Outperform |
| 2020-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-27 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Ripresa | Guggenheim | Buy |
| 2019-06-28 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Ripresa | Guggenheim | Buy |
| 2019-04-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Iniziato | Berenberg | Buy |
| 2018-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-03-21 | Downgrade | Citigroup | Buy → Neutral |
| 2016-12-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2016-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2016-06-13 | Iniziato | Citigroup | Buy |
| 2016-06-13 | Iniziato | Guggenheim | Buy |
| 2016-06-13 | Iniziato | Wedbush | Outperform |
Mostra tutto
Merus N V Borsa (MRUS) Ultime notizie
Dividend Watch: Is Merus NV being accumulated by smart moneyMarket Sentiment Review & Consistent Profit Trade Alerts - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Wells Fargo Downgrades Merus N.V. (MRUS) - MSN
Aug Summary: Is Merus NV a good ESG investment2025 Big Picture & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Biotechnology Gem With 7.78% Potential Upside - DirectorsTalk Interviews
Bank of America Securities Maintained a Buy Rating on Merus N.V (MRUS) - MSN
What is Merus N.V. s 5 year growth outlookWeekly Stock Summary & AI Enhanced Trading Signals - mfd.ru
Targets Report: Will Merus N.V. stock outperform tech sector in 2025Weekly Trade Summary & Reliable Momentum Entry Alerts - mfd.ru
Genmab Prepares For Two Product Launches In 2027, Both From Recent Deals - Citeline News & Insights
Is Merus N.V. stock trading near support levelsJuly 2025 PostEarnings & Intraday High Probability Setup Alerts - mfd.ru
Published on: 2026-02-10 12:58:35 - mfd.ru
Can Merus N.V. reach all time highs this year2025 Major Catalysts & Proven Capital Preservation Methods - mfd.ru
Merus N.V. (MRUS) Stock Analysis: Weighing The 7.78% Potential Upside For Investors - DirectorsTalk Interviews
Merus N.V. (MRUS) Stock Analysis: Exploring the Potential 7.78% Upside in the Biotech Sector - DirectorsTalk Interviews
Analyst Downgrade: Is Merus NV gaining market shareJuly 2025 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
Growth Recap: What are Can Fite BioPharma Ltd Depositary Receipts technical support levels - baoquankhu1.vn
Aug Ideas: Is Merus NV a turnaround storyJuly 2025 PreEarnings & AI Enhanced Execution Alerts - baoquankhu1.vn
Fourteen option delistings on January 21st - TipRanks
Merus N.V. (MRUS) Stock Analysis: Biotechnology Innovator With 7.78% Upside Potential - DirectorsTalk Interviews
Piper Sandler sets $84 target on Merus stock, cites drug potential - MSN
S P Trends: How does Merus NV correlate with Nasdaq2025 Technical Overview & Target Return Focused Picks - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Healthcare Innovator With 7.78% Upside Potential - DirectorsTalk Interviews
Gap Down: Is Merus N.V. stock a safe haven assetJuly 2025 Trade Ideas & Risk Controlled Swing Alerts - Bộ Nội Vụ
Aug Breakouts: Why Merus NV stock could benefit from AI revolutionJuly 2025 Final Week & Stock Market Timing Techniques - Bộ Nội Vụ
Risk Report: Will Merus NV stock benefit from M A activityQuarterly Market Summary & Pattern Based Trade Signal System - Bộ Nội Vụ
Aug Shorts: Is Merus NV stock a buy on dipsEarnings Growth Summary & Low Risk Entry Point Tips - Bộ Nội Vụ
(MRUS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Published on: 2026-01-13 00:53:02 - Улправда
Merus N.V.Common Shares (NQ: MRUS - FinancialContent
How Merus N.V. stock trades before earnings2025 Market Overview & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Net current asset value per share of Merus N.V. – MUN:2GH - TradingView — Track All Markets
Why Merus N.V. stock attracts high net worth investorsQuarterly Performance Summary & Reliable Entry Point Trade Alerts - ulpravda.ru
Is Merus N.V. (2GH) stock positioned for digital growth eraDay Trading Setups & Free Tools to Monitor Market Corrections - Улправда
Merus N.V. Financial Disclosures & Filings - TradingView — Track All Markets
Merus N.V. (MRUS) Stock Analysis: Exploring a 7.78% Potential Upside Amid Biotech Innovations - DirectorsTalk Interviews
Genmab Announces $2.5 Billion Note Offering for Merus Acquisition - MSN
What analysts say about Merus NV stockTrading Volume Surges & Outstanding Investment Returns - earlytimes.in
Retail Trends: How Merus NV 2GH stock moves in volatile trading sessionsProduct Launch & Free Expert Verified Stock Movement Alerts - moha.gov.vn
Why retail investors favor Merus N.V. stockEconomic Indicators Overview & Low Risk Capital Growth Plans - bollywoodhelpline.com
Moody Aldrich Partners LLC Reduces Position in Merus N.V. $MRUS - MarketBeat
Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus - ts2.tech
A/S Genmab Purchases 1,052,806 Shares of Merus (NASDAQ:MRUS) Stock - MarketBeat
Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout - ts2.tech
Genmab completes acquisition of Merus and delists shares from Nasdaq By Investing.com - Investing.com Australia
Merus Completes Genmab Acquisition and Delists From Nasdaq - TipRanks
Merus completes Genmab acquisition and delists from Nasdaq - MSN
Genmab completes acquisition of Merus and delists shares from Nasdaq - Investing.com
Merus Announced Transfer or Voluntary Withdrawal of Listing - TradingView — Track All Markets
Simplify Asset Management Inc. Takes $3.14 Million Position in Merus N.V. $MRUS - MarketBeat
Genmab to discontinue further development of acasunlimab - Yahoo Finance
Merus (NASDAQ:MRUS) Major Shareholder A/S Genmab Acquires 96,082 Shares - MarketBeat
Merus N V Azioni (MRUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
2.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):